Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announce that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline. The combined company will focus on advancing TuHURA’s personalized cancer vaccine(s) and first-in-class bi-functional ADCS.
Read the full article: Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement //
Source: https://www.prnewswire.com/news-releases/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement-302106737.html